Original Article

You have full text access to this OnlineOpen article

The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy†‡

Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

  1. Stephen J. Freedland M.D.1,§,¶,‖,*,
  2. William J. Aronson M.D.1,2,¶,
  3. Martha K. Terris M.D.3,¶,
  4. Christopher J. Kane M.D.4,¶,
  5. Christopher L. Amling M.D.5,¶,
  6. Frederick Dorey Ph.D.6,¶,
  7. Joseph C. Presti Jr. M.D.7,¶

Article first published online: 20 OCT 2003

DOI: 10.1002/cncr.11809

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2344–2350, 1 December 2003

Additional Information

How to Cite

Freedland, S. J., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., Dorey, F. and Presti, J. C. (2003), The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy. Cancer, 98: 2344–2350. doi: 10.1002/cncr.11809

Author Information

  1. 1

    Department of Urology, University of California–Los Angeles, Los Angeles, California

  2. 2

    Department of Surgery, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California

  3. 3

    Section of Urology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California

  4. 4

    Department of Urology, University of California–San Francisco, San Francisco, California

  5. 5

    Department of Urology, Naval Medical Center, San Diego, California

  6. 6

    Department of Biostatistics, University of California–Los Angeles, Los Angeles, California

  7. 7

    Department of Urology, Stanford University School of Medicine, Palo Alto, California

  1. §

    Brady Urological Institute, Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland

  1. All authors are members of the SEARCH Database Study Group.

  2. ‖

    Fax: (410) 502-9336

*Brady Urological Institute, Department of Urology, Marburg 130, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287

  1. †

    The opinions expressed herein do not necessarily reflect the views of the Department of Veterans Affairs or of the U.S. Government.

  2. ‡

    This article is a U.S. Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 20 OCT 2003
  3. Manuscript Accepted: 27 AUG 2003
  4. Manuscript Revised: 14 JUL 2003
  5. Manuscript Received: 7 MAY 2003

Funded by

  • Department of Veterans Affairs
  • Center for Prostate Disease Research
  • United States Army Medical Research and Material Command

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (90K)

REFERENCES

  • 1
    D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000; 18: 1164–1172.
  • 2
    Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002; 59: 560–565.
  • 3
    Presti JC Jr., Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998; 52: 1079–1084.
  • 4
    Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002; 167: 516–520.
  • 5
    Freedland SJ, Aronson WJ, Terris MK, et al. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of PSA recurrence following radical prostatectomy: results from the SEARCH database. J Urol. 2003; 169: 2136–2141.
  • 6
    Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002; 60: 670–674.
  • 7
    Terris MK. Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report. Urology. 1999; 54: 486–489.
  • 8
    Borirakchanyavat S, Bhargava V, Shinohara K, Toke A, Carroll PR, Presti JC Jr. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology. 1997; 50: 373–378.
  • 9
    Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000; 56: 87–91.
  • 10
    Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000; 163: 158–162.
  • 11
    Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982; 247: 2543–2546.
  • 12
    D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969–974.
  • 13
    Freedland SJ, Aronson WJ, Presti JC Jr., et al. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003; 169: 2129–2135.
  • 14
    Ou YC, Chen JT, Yang CR, et al. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol. 2002; 32: 172–176.
  • 15
    Graefen M, Haese A, Pichlmeier U, et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol. 2001; 165: 857–863.
  • 16
    Elliott SP, Shinohara K, Logan SL, Carroll PR. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer. J Urol. 2002; 168: 105–109.
  • 17
    Presti JC Jr., Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000; 163: 163–166.
  • 18
    Gore JL, Shariat SF, Miles BJ, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001; 165: 1554–1559.
  • 19
    Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002; 59: 740–745.
  • 20
    D'Amico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000; 55: 572–577.
  • 21
    Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. Substratification of Stage T1C prostate cancer based on the probability of biochemical recurrence. Urology. 2002; 60: 1034–1039.
  • 22
    Linson PW, Lee AK, Doytchinova T, et al. Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology. 2002; 59: 704–708.
  • 23
    Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000; 163: 174–178.
  • 24
    Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am. 2001; 28: 459–472.
View Full Article (HTML) Get PDF (90K)